Abstract:Objective To study the pharmacokinetics of the first-line anti-tuberculosis drugs including rifampicin,isoniazid,and ethambutol in a cohort of Chinese patients with tuberculosis and to determine the relationship between the pharmacokinetic parameters of these anti-tuberculosis drugs and the clinical treatment outcomes.Methods A prospective study was conducted to recruit patients diagnosed with pulmonary tuberculosis from the Inpatient Department of the Wenzhou Central Hospital from October 1,2015 to January 31,2016.A total of 72 patients were enrolled.Subjects were initially treated or retreated once,and both bacteriologically confirmed and clinically diagnosed cases were eligible.Plasma samples were collected 0.5 h before and 2 h,4 h,6 h,8 h after taking standard quadruple drugs for one week doses.Plasma concentrations were determined using LC-MS/MS.Patients were followed up 2 months after the initiation of treatment to assess the relationships between sputum negative conversion and plasma concentrations.Results Among the 72 patients,one patient was confirmed to have multidrug-resistant tuberculosis and one patient was lost to follow up.Thus,70 patients were analyzed at last,among whom 16 patients were bacteriologically negative and 54 patients were bacteriologically positive at initial diagnosis.The plasma exposures at steady state after one week of drug administration were analyzed.25.7％ (18/70) patients had a plasma peak concentration (Cmax) of rifampicin lower than the recommended range (＜8 μg/ml),38.6％ (27/70) cases had a Cmax of isoniazid lower than the recommended range (＜3 μg/ml),whereas 65.7％ (46/70) patients had a Cmax of ethambutol lower than the recommended range (＜2 μg/ml).After 2-month of treatment,among the 54 patients who were sputum bacteria positive at initial diagnosis,48 patients conversed to sputum bacteria negative,while sputum bacteria were still detected in 6 patients.The C2h,Cmax,and AUC0-8 of ethambutol were significantly higher in patients who got sputum conversion after 2-month of treatment ((1.81± 0.91) μg/ml,(1.81±0.85) μg/ml,and (7.67±3.25)μg · h · m1-1) compared with those who failed to get sputum conversion ((0.93±0.32)μg/ml,(1.06±0.25)μg/ml,and (4.93±0.72) μg · h · ml-1) (t=4.74,P＜0.01;t=4.93,P＜0.01;and t=4.95,P＜0.01,respectively).The C2 h and Cmax of isoniazid were significantly higher in patients who got sputum conversion after 2-month of treatment ((3.67±1.64) μg/ml and (3.85±1.59) μg/ml) compared with those who failed to get sputum conversion ((2.11±1.14)μg/ml and (2.11±1.14) μg/ml) (t=2.60,P=0.012;t=2.25,P=0.029,respectively).Conclusion The Cmax of drugs below the recommended reference ranges,especially isoniazid and ethambutol,were observed in some patients with pulmonary tuberculosis.The dosage of isoniazid and ethambutol may need to be modified.In addition,the sputum negative conversion after 2-month of treatment was shown to be related with the serum concentration of isoniazid and ethambutol.

Time to sputum culture conversion and its associated factors among drug-resistant tuberculosis patients: a systematic review and meta-analysis

Evaluation of time to sputum smear conversion and its association with treatment outcomes among drug-resistant tuberculosis patients: a retrospective record-reviewing study

A study on factors influencing delayed sputum conversion in newly diagnosed pulmonary tuberculosis based on bacteriology and genomics

Sputum Bacteriology Conversion and Treatment Outcome of Patients with Multidrug-Resistant Tuberculosis

Determinants of sputum culture conversion time in multidrug-resistant tuberculosis patients in ALERT comprehensive specialized hospital, Addis Ababa, Ethiopia: A retrospective cohort study

Longitudinal Molecular Epidemiological Study of Multidrug Resistant Tb and Transition to Extensively Drug Resistance in Eastern Rual China

Time for culture conversion and its associated factors in multidrug-resistant tuberculosis patients at a tertiary level hospital in Peshawar, Pakistan

INCIDENCE AND FACTORS ASSOCIATED WITH LATE SPUTUM CULTURE CONVERSION AMONG MULTI- DRUG RESISTANT TUBERCULOSIS PATIENTS ON TREATMENT IN NATIONAL REFERRAL HOSPITAL UGANDA

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis

Time to Sputum Smear Conversion and Its Predictors Among Smear-Positive Pulmonary TB Patients in East Gojjam Zone, Northwest Ethiopia: A Longitudinal Study.

Predictors of early and interim culture un-conversion in multidrug-resistant/rifampicin-resistant tuberculosis: a retrospective multi-center cohort study in China

The relationship between plasma concentrations of the first-line anti-tuberculosis drugs and sputum negative conversion at early stage

Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis

Sputum smear conversion and associated factors among smear-positive pulmonary tuberculosis patients in East Gojjam Zone, Northwest Ethiopia: a longitudinal study

Prevalence and Patterns of Drug-Resistant Mycobacterium tuberculosis in Newly Diagnosed Patients in China: A Systematic Review and Meta-Analysis

Body Mass Index a Forecast of Sputum Culture Conversion Among Drug-Resistant Tuberculosis Patients

Radiographic characteristics of rifampicin-resistant tuberculosis in the STREAM stage 1 trial and their influence on time to culture conversion in the short regimen

Characteristics and Trend of Drug-Resistant Tuberculosis at a Major Specialized Hospital in Chongqing, China: 2016 Versus 2019

Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis

Diagnostic Accuracy of Nanopore Sequencing for the Rapid Diagnosis of Pulmonary Tuberculosis: A Protocol for a Systematic Review and Meta-Analysis

Dynamic changes of respiratory microbiota associated with treatment outcome in drug-sensitive and drug-resistant pulmonary tuberculosis